News
02.11.2021

Get ready for EU CTR implementation with Cromos Pharma

The implementation of the European Union (EU) Clinical Trial Regulation (Regulation (EU) No 536/2014) (CTR) will bring about significant changes to the way clinical trials are conducted in the EU. The Clinical Trials Information System (CTIS) is set to go live on the 31 January 2022 with a transition period of 3 years planned for full migration to the new system.  In this article Cromos Pharma’s Head of Central European Operations, Zsolt Kocsis, considers some of the key changes ahead.

Background 

The EU CTR will replace the European Clinical Trials Directive (2001/20/EC) and is intended to harmonize the registration, assessment and supervision of clinical trials across all member states via the CTIS. The CTIS, set up and maintained by the EMA, will host the EU Portal and Database for all EU clinical trials.   

Scope of EU CTR 

The Regulation covers interventional clinical trials with medicinal products for human use. A new category of low-intervention clinical trials with adapted requirements also falls under the Regulation. These are:

  • The investigational medicinal products (IMP) are authorized; 

  • If the IMP is not used in accordance with the terms of the MA, that use is supported by published scientific evidence on S&E; 

  • Minimal additional risk or burden to the safety of the subjects compared to normal clinical practice. 

Non-interventional trials and trials without medicinal products (e.g., devices, surgery) are not covered.

Key changes 

  • Single e-submission via an EU portal CTIS. 
  • Coordinated assessment and one single decision per Member State.
  • Introducing a risk adapted approach by applying less stringent rules to those trials conducted with medicines which are already authorized, and which pose only minimal risk compared to normal clinical practice.
  • Increasing transparency regarding clinical trials and their outcomes.
  • Simplifying safety reporting requirements.
  • Reinforcing supervision of clinical trials by introducing Union Controls in Member States and third countries to ensure that the Regulation is properly supervised and enforced.
  • Provisions concerning clinical trials conducted outside the EU but referred to in a clinical trial application within the EU, which will have to comply with regulatory requirements that are at least equivalent to those applicable in the EU.
  • Introducing the concept of co-sponsorship.
  • Informed consent - new provisions for:
    • Broad consent (use of data outside the protocol)
    • Simplified consent for certain cluster trials
    • For trials in minors and incapacitated subjects
    • For trials on pregnant and breastfeeding women
    • Member States to maintain measures for other vulnerable groups (e.g., persons in military service, deprived of liberty)
    • Additional detail for conducting trials in the emergency setting
  • Damage compensation system to be set up by the Member States.
  • Designation of national contact points by Member States.
  • Archiving of the Trial Master File for 25 years. 

Transparency

One of the main aims of the EU CTR is to increase transparency in relation to clinical trials. The new CTIS will be public by default but subject to limited exceptions including those related to personal data and commercially sensitive data. The goal is to allow public access to information on clinical trials so that patients can more easily access trials which may be suitable for them, find out the outcomes of trials they have participated in, and understand what is known about a medicine they have been prescribed.  

In addition, greater transparency is aimed at allowing sponsors to access data on clinical trial outcomes to support marketing authorization, find out if a clinical trial they are designing has already been conducted, and if any problems have occurred in similar trials. It is important to note that the regulation takes a balanced approach to the issue of transparency weighing carefully the public interest with the interests of sponsors and researchers to protect their investment.

Transition period 

The CTR will come into application in January 2022 with a 3 year transition period. During the first year of this period clinical trials can be submitted under the old or new systems. In years 2-3, trials submitted under the old system will remain under that system. After that all clinical trials must be submitted under new system (January 2025).

Key takeaways 

The EU CTR aims to foster greater harmonization in relation to the conduct of clinical trials through its single point of entry model.  It aims to support greater Member State collaboration by allowing for one single decision per Member State concerned. The platform used, CTIS, will be maintained and updated by the EMA. A key principle underlying the Regulation is to promote greater transparency and increase public knowledge about the conduct and results of clinical trials and promote trust and confidence in the drug development process. 

Cromos Pharma and EU CTR 

Cromos Pharma has in-depth regulatory expertise and experience in supporting pharma and biotech sponsors to navigate regulatory complexities. Our team is ready to help in smoothing the transition to the EU CTR by advising on protocol language and necessary new processes and ensuring compliance with new requirements. 

Click here for more information about the EU CTR

LEARN HOW CROMOS PHARMA CAN HELP YOU ACHIEVE COMPLIANCE AND GAIN MAXIMUM BENEFITS FROM THE EU CTR BY EMAILING US AT INQUIRY@CROMOSPHARMA.COM

 

Other News:
news

Reasons why Georgia needs to be on your list of locations for clinical trials

With its rapid regulatory approval process, significant naïve populations in a range of therapeutic areas, skilled medical personnel and a conducive economic environment for doing business Georgia is regarded as a hidden gem for those interested in initiating novel studies and rescue trials. 
06.04.2021
news

Simple Math for Clinical Trial Success

Today we launched a brand new video Simple Math with Cromos Pharma showing you how we can help ensure your clinical trial's success. 
31.03.2021
news

Colorectal Cancer: A survivor's story

Throughout March we have been highlighting colorectal cancer, the amazing teams of researchers who are continuously fighting this disease, as well as the millions of patients and families who have been deeply affected by this silent killer. To close out this month of awareness-raising we want to introduce you to a real-life hero and colon cancer survivor - Arlene.

30.03.2021
news

Colorectal Cancer Awareness Month

March is Colorectal Cancer Awareness Month. Colorectal cancer (CRC) is the third most common and second most deadly cancer worldwide according to 2020 figures from the Global Cancer Observatory. 

25.03.2021
news

Data management and Biostatistics solutions to ensure the quality of your data

Effective data management and biostatistics are crucial for producing high quality data for successful clinical trials. At Cromos Pharma our expert data management and biostatistics team provides innovative solutions to ensure transparency, data integrity and quality of your data.
23.03.2021
news

Cromos Pharma appoints new Business Development Director for Central and Eastern Europe

At Cromos Pharma we are constantly growing and developing expanding our horizons and building our capacity to deliver innovative clinical trials solutions across our global network of operations. Therefore, we are delighted to announce the appointment of Nataliya Artyushenko as our new Business Development Director for Central and Eastern Europe.
21.03.2021
news

Reasons to choose Ukraine as the location for your next clinical trial

Ukraine, the eight largest European country by population, is an attractive location for sponsors conducting clinical research for a number of key reasons. Cromos Pharma has been successfully managing clinical trials in Ukraine since 2006. This article looks at just some of the benefits of locating your next study here.

16.03.2021
news

Cromos Pharma charting new territories as it looks east to Uzbekistan

Cromos Pharma is continuously developing and looking to explore new territories when it comes to clinical research. In line with this spirit of discovery, we will be shortly commencing a new project in Uzbekistan supporting a study being conducted by the Swiss Tropical and Public Health Institute. 

11.03.2021
news

IWD2021: Championing Women making healthcare breakthroughs

March 8th is International Women’s day, a global day of celebration of the social, political cultural and economic achievements of women. It is also a day for promoting the goal of greater gender parity across all sections of society. At Cromos Pharma, we are using this day to celebrate just a few of the many trailblazing women in healthcare.
08.03.2021
news

Cromos CEO outlines advantages of Central and Eastern Europe for clinical trials

Thinking about Eastern Europe as a venue for your clinical trial? Cromos Pharma CEO Vlad Bogin outlines some of the advantages in this new interview.
04.03.2021
news

Rare diseases and drug development

The World Economic Forum estimates that 475 million people worldwide are affected by a rare disease. To mark World Rare Disease Day (28 February 2021), in this article Stephanie Finnegan, Cromos Pharma’s COO, explores the opportunities and challenges for rare disease drug development.
26.02.2021
news

Key factors to consider for rare disease/orphan drug development

To mark World Rare Disease Day (28th February 2021), Cromos Pharma's Head of Start-Up outlines some of the key factors to consider for rare disease/orphan drug clinical trials.
26.02.2021
news

Connect with us at DIA Europe and BIO-Europe this March

Cromos Pharma is delighted to be taking part in the upcoming DIA Europe conference (15 – 19 March 2021) and BIO-Europe Spring (22-25 March 2021).

 

15.02.2021
news

International Women and Girls in Science Day

February 11th is International Women and Girls in Science Day. A joint UNESCO and UN-Women initiative, it aims to promote the role of #WomenInScience and to challenge some of the barriers to girls pursuing a career in science.

11.02.2021
news

Top 5 reasons to locate your next clinical trial in Hungary

Discover some of the reasons why you should consider Hungary as a location for your next clinical trial.
09.02.2021
news

Cromos Pharma offers EU Legal Representative Service

Are you a sponsor seeking to conduct clinical trials in the European Union but do not have a registered office in the European Economic AreaIf so, in order to comply with the European Union Clinical Trial Directive, you are required to work with a Legal Representative registered in an EEA country.

04.02.2021
news

World Cancer Day 2021: Cromos Pharma is committed to supporting clinical research to make cancer breakthroughs

Each 4th February, #WorldCancerDay aims to raise awareness of the global personal, social and economic burden of cancer. World Cancer Day was established in Paris at the first World Cancer Summit in 2000.

 


04.02.2021
news

European Medicines Agency: Approvals January 2021

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) recommended 13 new medications for approval and three therapeutic indication extensions in its January 2021 meeting.
31.01.2021
news

Upcoming EU drug/device legislation: What you need to know

Zsolt Kocsis, Cromos Pharma's Head of EU Operations explores some of the upcoming changes to EU legislation in relation to drug development and medical devices. 
25.01.2021
news

Reaping the benefits of a Euro-Australian collaboration for biotechs: save on costs and time

Cromos Pharma CEO Dr Vlad Bogin is joined by Avance Clinical's CEO Yvonne Lungershausen to discuss some of the benefits available to biotechs by availing of a joint initiative that combines Australian tax benefits for clinical research with exceptional patient recruitment and retention in Eastern European markets.
24.01.2021
news

Clinical trials in the time of COVID: Risks, mitigation and lessons learned

Clinical trials in the time of COVID: Risks, mitigation and lessons learned presented by Stephanie Finnegan, COO Cromos PharmaIn this presentation she looks at risks, how to mitigate crisis management, and what the sector has learned since being forced into some major changes due to COVID-19. 

24.01.2021
news

Clinical trials: how to enroll on time, stay on budget and not compromise data quality

Stephanie Finnegan, COO of Cromos Pharma delivers key insights into how to maintain study and data integrity when facing cost and time constraints. When time and money is of the essence how can you achieve patient recruitment targets? 
23.01.2021
news

Global vaccine rollout underway as COVID-19 cases surge

As 2021 begins, many countries are grappling with a renewed surge of COVID-19 infections necessitating further public health restrictions putting more pressure on health systems, societies and global economies.  The task of rolling out approved vaccines is increasingly urgent. Almost 16 million doses of COVID-19 vaccines have been administered to date in 37 countries worldwide according to data compiled by Bloomberg ( updated 7 Jan 2021). 

07.01.2021
news

JP Morgan Healthcare Conference: Virtual Booth and Daily Presentations

We have been meeting you at the JP Morgan Healthcare Conference for the past 11 years and there is no way we are going to break with this tradition. Meet us at the CROMOS PHARMA VIRTUAL BOOTH January 11th through 14th from 8 am to 5 pm(PST). Learn about some of the most vital issues in clinical research by attending our daily presentations or stop by anytime for a chat.


01.01.2021
news

Seasons Greetings from Cromos Pharma

Seasons Greetings from everyone at Cromos Pharma. Watch our holiday video here>>
22.12.2020
news

Watch: The benefits of Cromos Pharma and Avance Clinical's biotech initiative

In October we launched an exciting collaboration with Avance Clinical to offer biotechs a scalable clinical trials solution. The collaboration allows biotechs to quickly start their pre-IND early phase studies in Australia, then expand to Central/Eastern Europe to access the large patient populations for their Phase 2 and 3 studies. In this new video you can learn more about the benefits of this initiative.


08.12.2020
news

World AIDS Day 2020: Remarkable progress but the fight continues

Tuesday 1 December marked World AIDS Day 2020. Although throughout this year our focus has been on the coronavirus pandemic, World AIDS Day is an opportunity to reflect on another pandemic where a virus passed from animals to humans with devastating consequences. To date 77 million people worldwide have been infected with HIV. In spite of innovative new treatments 35 million people have died from the virus. 

01.12.2020
news

Thanksgiving Greetings

Thanksgiving Greetings from everyone at Cromos Pharma. Watch our video here.
20.11.2020
news

World Pancreatic Cancer Awareness Day 2020

Thursday 19 November 2020 is World Pancreatic Cancer Awareness Day. Here at Cromos Pharma we are proud to play our part in supporting clinical trials aimed at finding better treatments for pancreatic cancers. 

19.11.2020
news

FDA Offers Guidance to Enhance Diversity in Clinical Trials

The FDA released a statement (9 November 2020) outlining its commitment to promoting greater diversity in medical product development and issuing a new guidance document outlining the agency's thinking on encouraging greater inclusivity “Enhancing the Diversity of Clinical Trial Populations--Eligibility Criteria, Enrollment Practices, and Trial Designs,”
12.11.2020
news

Cromos Pharma and Avance Clinical share details of innovative collaboration at BIO-Europe 2020

Cromos Pharma and Avance Clinical announced details of their innovative collaboration to offer biotechs scalable clinical trial solutions at BIO-Europe 2020.
28.10.2020
news

Orphan Drugs Market to Reach USD 340.84 Billion by 2027

The global orphan drugs market size is projected to reach USD 340.84 billion by the end of 2027. Increasing number of regulatory approvals will have a positive impact on the growth of the overall market in the coming years according to a new report from Fortune Business Insights
26.10.2020
news

Cromos Pharma and Avance Clinical launch scalable clinical trial solution for biotech

Cromos Pharma is delighted to announce a new collaboration with Avance Clinical providing a scalable clinical trial solution for biotech.
08.10.2020
news

Video: Cromos Pharma and Avance Clinical Collaboration

Cromos Pharma and Avance Clinical are joining forces to offer a scalable clinical trial solution for biotechs. Watch the video to find out more>>
08.10.2020
news

Alzheimer's Awareness Month: Q&A with Dr Sabina Brennan

September is World Alzheimer’s Month. Alzheimer’s Disease (AD) is the most well-known form of dementia. Dementia is the collective name for progressive brain conditions affecting memory, thinking, behavior and emotions. Dementia affects almost 50 million people worldwide. While aging is a major risk factor for dementia, it also affects people under 65 years. To mark Alzheimer’s Awareness Month (Sept 2020) we sat down with leading psychologist, neuroscientist and best-selling author Dr Sabina Brennan. Dr Brennan is a brain health expert who has advised Irish and UK governments on policies relating to aging and dementia.  She is the Irish national representative on the Medical and Scientific Advisory Panel for Alzheimer’s Disease International.
28.09.2020
news

Watch Webinar: Where in the world should I locate my pivotal clinical trial?

If you missed the live webinar “Where in the world should I locate my pivotal clinical trial?” you can now watch the recording by clicking hereThe webinar hosted by the Society of Physician Entrepreneurs (SoPE) and Workforce Genetics features Cromos Pharma's CEO Vlad Bogin, M.D, FACP. 


24.09.2020
news

Watch our video: Navigating an era of uncertainty

We are pleased to share with you our new video Cromos Pharma: Helping to navigate an era of uncertainty.

02.09.2020
news

Webinar: Where in the world should I locate my pivotal clinical trial?

01.09.2020